Longtime CMO Jon Bridges steps down as Chick-fil-A enters its 80th anniversary year. Michael Lage, a 14-year company veteran with digital and operations experience, will take the helm after a transition period.
Social media investigations reveal widespread weight mislabeling on Walmart meat products, prompting potential legal action and raising questions about pricing integrity at the retail giant.
After soaring to unprecedented highs, copper prices have begun to retreat. Goldman Sachs forecasts a more significant market adjustment by mid-2026, driven by potential U.S. tariff policies and a disconnect from fundamental demand.
Chinese autonomous driving leader WeRide has launched its proprietary general-purpose simulation model, Genesis, designed to bridge the gap between real-world data and virtual testing. The platform promises to drastically cut development time and costs for AV systems, from advanced driver-assistance features to fully autonomous robotaxis.
A stunning reversal wiped out months of gains for precious metals on Friday, with gold futures tumbling to $4,800 and silver recording a historic single-day drop, sparking fears of a volatile new phase for commodity markets.
A sharp, unexpected jump in wholesale prices complicates the White House's economic narrative and its pressure campaign on the Federal Reserve for rate cuts.
Secretary-General Antonio Guterres has issued his starkest warning yet, stating the United Nations' deepening liquidity crisis threatens its operations and risks a financial meltdown, driven by unpaid dues and an antiquated budget rule.
Morgan Stanley and Barclays have both lowered their price targets for Appalachian Basin natural gas leader Antero Resources (AR), citing revised commodity forecasts. Despite the cuts, Morgan Stanley maintains an 'Overweight' rating, signaling continued confidence in the stock's long-term trajectory.
President Trump's nomination of former Fed Governor Kevin Warsh to lead the central bank has ignited market speculation over the future path of interest rates, with analysts divided on whether his leadership would mean more cuts or a return to hawkish restraint.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
Chevron capped off a year of strategic execution with record global production and industry-leading free cash flow growth, while outlining ambitious expansion plans from the Caspian to the Caribbean.
Amidst a choppy market, value investors are hunting for bargains. We spotlight three companies—Dingdong, Origin Bancorp, and ATRenew—whose current share prices appear significantly disconnected from their estimated intrinsic value, presenting potential opportunities for the discerning investor.
Despite posting a Q4 net loss, Covenant Logistics signals a shift in market dynamics, with executives pointing to rising spot rates, secured contract increases, and a disciplined fleet strategy as precursors to a stronger performance by late 2026.
Amid a cautiously optimistic market backdrop, companies where executives hold significant stakes are drawing investor attention. We examine three such firms where insider buying and strategic moves signal confidence in long-term growth.
Facing rising postpaid churn and prepaid losses, AT&T is aggressively pushing bundled phone and internet packages as its core retention strategy, betting that convergence can stem the tide of subscribers fleeing to rivals and cable companies.
MKS Instruments' recent €1 billion debt offering to refinance its balance sheet arrives as its stock rides a powerful rally, forcing investors to weigh strong operational momentum against a valuation that appears stretched.
Shares of diabetes care innovator Insulet have tumbled nearly 10% year-to-date, sparking a fierce debate among investors. While a key valuation model suggests the stock is deeply undervalued, its sky-high P/E ratio tells a conflicting story. We examine the numbers and what they mean for the future of the Omnipod maker.
Shares in Lloyds Banking Group have surged over 18% in three months, reigniting investor interest. As the stock hovers near analyst targets, a key question emerges: does the UK banking giant still offer value, or has the market run ahead of itself?
Visa is aggressively expanding its footprint beyond traditional card payments, launching new initiatives in stablecoin settlements, renter-focused commerce, and streamlined crypto-to-fiat conversions. These partnerships aim to embed Visa's network into the burgeoning worlds of blockchain-based finance and essential housing expenditures.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
